Huapont Life Sciences Co Ltd
SZSE:002004

Watchlist Manager
Huapont Life Sciences Co Ltd Logo
Huapont Life Sciences Co Ltd
SZSE:002004
Watchlist
Price: 5.41 CNY 3.05% Market Closed
Market Cap: ¥10.7B

EV/EBIT

30.9
Current
133%
More Expensive
vs 3-y average of 13.3

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
30.9
=
Enterprise Value
¥14B
/
EBIT
¥448.1m

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
30.9
=
Enterprise Value
¥14B
/
EBIT
¥448.1m

Valuation Scenarios

Huapont Life Sciences Co Ltd is trading above its 3-year average

If EV/EBIT returns to its 3-Year Average (13.3), the stock would be worth ¥2.32 (57% downside from current price).

Statistics
Positive Scenarios
1/4
Maximum Downside
-63%
Maximum Upside
+24%
Average Downside
26%
Scenario EV/EBIT Value Implied Price Upside/Downside
Current Multiple 30.9 ¥5.41
0%
3-Year Average 13.3 ¥2.32
-57%
5-Year Average 11.5 ¥2.02
-63%
Industry Average 38.3 ¥6.69
+24%
Country Average 28.9 ¥5.06
-7%

Forward EV/EBIT
Today’s price vs future ebit

Not enough data available to calculate forward EV/EBIT

Peer Comparison

All Multiples
EV/EBIT
P/E
All Countries
Close

Market Distribution

In line with most companies in China
Percentile
52nd
Based on 5 337 companies
52nd percentile
30.9
Low
0 — 16.6
Typical Range
16.6 — 52.9
High
52.9 —
Distribution Statistics
China
Min 0
30th Percentile 16.6
Median 28.9
70th Percentile 52.9
Max 49 021

Huapont Life Sciences Co Ltd
Glance View

Market Cap
10.7B CNY
Industry
Chemicals

Huapont Life Sciences Co., Ltd., a prominent player in the global pharmaceutical and agrochemical sector, finds its roots in the bustling city of Chongqing, China. Established in 1992, the company swiftly evolved from a regional upstart to a substantial force in the life sciences industry. Huapont's narrative is grounded in its strategic blend of pharmaceutical prowess and agrochemical dexterity. The company's pharmaceutical operations primarily focus on the development, production, and marketing of dermatological and anti-tuberculosis drugs, riding on China's expansive healthcare reforms and increasing demand for specialized medical treatments. This niche approach allows Huapont to capture a substantial share of the market, offering innovative solutions that cater to rising public health concerns. Parallel to its medical endeavors, Huapont has cultivated a robust agrochemical arm. The company leverages advanced research and development to produce and distribute a wide range of crop protection products, including herbicides, fungicides, and insecticides. This diversification in agrochemicals keeps Huapont resilient amidst agricultural cycles and global market fluctuations, providing a steady stream of revenue. By interweaving pharmaceutical advancements with agricultural science, Huapont effectively taps into two essential human needs: health and sustenance. Through these dual pillars, the company harmoniously balances its portfolio, drawing upon scientific research and market insights to drive sustainable growth and enduring value for its stakeholders.

Intrinsic Value
6.35 CNY
Undervaluation 15%
Intrinsic Value
Price ¥5.41
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett